| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2540915 | International Immunopharmacology | 2012 | 7 Pages |
BackgroundSignificant efforts are dedicated to identification of agents that eliminate anti-HLA antibodies (Ab) from sera of transplant candidates. Antibody titer following in vitro incubation of sera with desensitizing agents has shown to reflect the probability that a patient would benefit from clinical de-sensitization protocols. AS101 is a non-toxic, synthetic, organic tellurium compound. The aim of this research was to assess the ability of AS101 to reduce anti-HLA Abs and to identify patients likely to benefit from this effect.MethodsSera of sensitized patients awaiting transplant were incubated in the presence of AS101. Measured mean fluorescence intensity (MFI) represents reactivity of anti HLA Abs in the serum, as detected by the Luminex platform. The repertoire of HLA antigen epitopes was recognized using HLA Matchmaker software.ResultsAS101 Incubation caused a significant Ab titer decrease in approximately two thirds of the samples. The median Class I and II MFI decrease among the responding samples was 16.7% and 14%, respectively (p < 0.05). HLA Matchmaker analysis of the patients' class I epitope sequences revealed apparent amino-acid differences between the patterns of the responding and non-responding patients.ConclusionIn vitro incubation of sera in the presence of AS101 causes a decrease in the anti-HLA Ab's reactivity in several patient samples. Sera most likely to demonstrate this effect are characterized by a moderate MFI level and a distinct antibody reactivity pattern specific for defined HLA antigen epitopes. These results support further investigation of AS101 as a potential agent for desensitization of humoral reactivity prior to transplantation.
► Anti-HLA antibodies remain an substantial barrier to transplantation. ► in vitro immunomodulation may decrease reactivity of anti HLA antibodies in sera. ► Incubation with AS101 decreased antibody reactivity in selected sensitized sera. ► Structural characteristics of antibodies may affect a serum's reactivity to AS101. ► We report findings of a structural based study of AS101 in eliminating antibodies.
